Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Clearside Biomedical, Inc. (CLSD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/02/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...|
Docs:
|
"Presentation",
"Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMD - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., February 2, 2023 - Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space , annou..." |
|
| 01/04/2023 |
SC 13D/A
| Hatteras Venture Advisors III, LLC reports a 6.1% stake in CLEARSIDE BIOMEDICAL, INC. |
| 01/04/2023 |
SC 13G/A
| WHITMORE BRADFORD T reports a 9.9% stake in Clearside Biomedical, Inc. |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/11/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended December 31, Year Ended December 31, 2021 2020 2021 2020 License and other revenue $ 25,687 $ 11 $ 29,575 $ 7,894 Operating expenses: Research and development 3,840 4,472 18,537 15,073 General and administrative 3,140 2,649 11,665 10,756 Total operating expenses 6,980 7,121 30,202 25,829 Income from operations 18,707 Other income 2 ̶— 1,003 — Other expense — — Net income $ 18,709 $ $ 376 $ Net income per share of common stock — basic and diluted $ 0.31 $ $ 0.01 $ Weighted average shares outstanding — basic 59,669,759 49,048,402 58,491,986 46,506,540 Weighted average shares outstanding — diluted 61,182,414 49,048,402 59,906,602 46,506,540 Balance Sheet Data December 31, December 31, 2021 2020 Cash and cash equivalents $ 30,436 $ 17,287 Accounts receivable 10,000 — ..." |
|
| 03/03/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| RTW INVESTMENTS, LP reports a 6.4% stake in Clearside Biomedical, Inc. |
| 02/09/2022 |
SC 13G/A
| Carmignac Gestion reports a 5.2% stake in Clearside Biomedical, Inc. |
|
|
|